Navigation Links
Omthera Pharmaceuticals Announces Positive Long Term Bioavailability Data Comparing Epanova™ to Lovaza®
Date:1/9/2012

the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 10, 2012 at 8:30 am PT.

About Epanova™

Epanova is a patent protected, novel, ultra-pure mixture of the free fatty acid forms of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omthera has developed a substantial body of data on Epanova, which points to an improved and more predictable bioavailability as compared to the ethyl ester form found in prescription Omega-3 products currently available.  Triglyceride lowering with Epanova was previously observed in two large, placebo-controlled, randomized, double-blind, Phase III studies involving 748 Crohn's Disease patients with normal triglyceride levels for ≥52 weeks; approximately 400 of which were treated with Epanova for remission of disease. In all studies performed to date, Epanova has demonstrated a very good safety and tolerability profile.

About Hypertriglyceridemia

Hypertriglyceridemia refers to a condition in which patients have high blood levels of triglycerides and is associated with increased risk of heart disease. It is one component of a range of lipid disorders collectively referred to as dyslipidemia. The overall dyslipidemia population in the U.S. is believed to be in excess of 100 million, with over 27 million of those diagnosed with hypertriglyceridemia (TGs greater than 200mg/dL) and an estimated 5 million with very high triglyceride levels (TGs greater than 500mg/dL). Very high triglycerides are associated with an increased risk of pancreatitis. Regulatory approval for the treatment of very high triglycerides is based on a significant reduction in the serum triglyceride levels.

About Omthera Pharmaceuticals, Inc.

Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately-held, specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia.  Led
'/>"/>

SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Omthera Pharmaceuticals, Inc. to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Omthera Pharmaceuticals, Inc. to Present at the 23rd Annual Piper Jaffray Health Care Conference
3. Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality
4. Omthera Pharmaceuticals, Inc. to Present at the Rodman and Renshaw 13th Annual Healthcare Conference
5. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
6. Christian S. Schade to Join Omthera Pharmaceuticals as Executive Vice President and Chief Financial Officer
7. Drs. Ben Machielse Joins Omthera Pharmaceuticals, Inc. as Chief Operating Officer
8. Omthera Pharmaceuticals, Inc. to Present at the 2011 Wells Fargo Securities Healthcare Conference
9. Omthera Pharmaceuticals, Inc. to Present at the BIO Windhover/Pharmaceutical Strategic Outlook 2011 Conference
10. Omthera Pharmaceuticals Raises $33.9 Million in Series B Funding Led by New Enterprise Associates
11. Omthera Pharmaceuticals, Inc. to Present at the 29th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  Omeros Corporation (NASDAQ: OMER ... Application (IND) to evaluate OMS824 in Huntington,s disease ... Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase 10 ... brain linked to a wide range of diseases ... OMS824 has shown promising results in animal models ...
(Date:5/23/2013)... -- Echo Pharma Acquisition Limited ("Royalty Pharma") announced today that ... from 90 percent to 50 percent of Maximum Elan ... the terms of the Revised Offer Document issued today, ... the terms of the Increased Offer, Royalty Pharma is ... for $12.50 per share in cash. The Increased Offer ...
(Date:5/23/2013)... Engeland, May 23, 2013 Nederland ... met lagere urinewegsymptomen geassocieerd met BPH Astellas ... dochteronderneming van Astellas Pharma Inc, gebaseerd in ... kondigde vandaag aan dat het Nederlandse College ter Beoordeling ... in Nederland. De handelsvergunning verleend voor VESOMNI ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 2Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 3Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 4Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 5Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 6Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 7Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 8Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 9Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share 10Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 2Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 3Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen 4
(Date:5/23/2013)... May 23, 2013 A medical malpractice ... Court (reference number 110504/2009) by Lori Mandel, an office ... Ms. Mandel $8.6 million. Ms. Mandel sought the medical ... led to further complications that affected the quality of ... , The plaintiff alleged that her doctor rendered conservative ...
(Date:5/23/2013)... May 23 2013 - New techniques in imaging ... from McGill University,s Montreal Neurological Institute, and his ... from epilepsy. The combination of electroencephalogram (EEG) ... more precise localization of the areas generating epileptic ... optimal ways of intervention, if appropriate. These ...
(Date:5/23/2013)... 2013 According to a new market ... Management; Subscriber Data Management (SDM); Telecom Application Server; Service ... (2013 – 2018)", published by MarketsandMarkets, the SDP Market ... a CAGR of 9.15% from 2013 to 2018. , ... , 84 Figures , 189 ...
(Date:5/23/2013)... Miami, FL (PRWEB) May 23, 2013 In ... in 7 years. This doesn’t mean, however, that Florida’s good ... National Hurricane Center . This year, he encourages residents, it ... During hurricane season 2013, forecasters are predicting there to be ... reports WUFT . With hurricane season lasting from June ...
(Date:5/23/2013)... Worldwide Power Products (WPP), a power-generation ... has licensed the rights to sell Hythane Company's ... burn a mixture of natural gas and diesel. WPP ... for sale and rental and will also sell ... WPP's service technicians will be certified to install the ...
Breaking Medicine News(10 mins):Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 2Health News:New York Law Journal Releases Top Medical Malpractice Case for 2012: NY Supreme Court Awards $8.6 Million to Plaintiff after Doctor's Misdiagnosis Led to Personal Injury 3Health News:New imaging techniques used to help patients suffering from epilepsy 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Service Delivery Platform (SDP) Market Is Growing at a CAGR of 9.15% & to Reach $6.94 Billion by 2018 - New Report by MarketsandMarkets 3Health News:As Hurricane Season Nears, Skylake Insurance Encourages Florida Residents To Prepare Early For Safety 2Health News:Worldwide Power Products Announces Partnership with Hythane Company to Offer OptiBlend™ Bi-Fuel Solution for Diesel Engines 2Health News:Worldwide Power Products Announces Partnership with Hythane Company to Offer OptiBlend™ Bi-Fuel Solution for Diesel Engines 3
... The Health Minister Iris Evans says that Albertans are hoping for ... ,On the other hand the Albertans are known ... has prepared the initial phase of the new health care plan ... also plans to introduce more reforms by the end of the ...
... be used for regeneration of broken bones in a new ... headed by York University and // researchers from UK and ... biology, sociology and Philosophy from York University is aimed at ... the treatment of bone defects and fractures. ,Professor ...
... India as eliminated Leprosy but still we have to eradicate ... increasing the awareness regarding the // transmission of the bacteria ... disease. ,Indian Health Minister Dr. Anbumani Ramadoss during ... completely eradicate the disease which as about a 1 Lakh ...
... Doctors in New South Wales are angry at a proposal to ... Carroll, spokesman for the medical staff council at Wagga // Base ... elective surgery every fourth Friday. ,"So it'd create a ... relatively small amount of money but at great cost to patient ...
... University of Texas has revealed that moderate physical activity ... in easing depression. // Other measures adopted by ... smoking are associated with adverse health effects. ... 40 individuals, diagnosed with depression. None of the study ...
... study conducted on the prevalence of diabetes in the Indian ... has been uncovered. // So far, such studies have ... cannot be applied to South Asians. ,The research ... Diabetes Research Centre, an association of the World Health Organization ...
Cached Medicine News:Health News:Prevention And Control Of Diabetes Crucial To Indian Population 2
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, electrode, closed or non-tapered end catheters and other devices for intervention....
Used to introduce large balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce large devices for vascular intervention....
Medicine Products: